

Consolidated Financial Results for Fiscal 2015

(Reference Data of Financial Statements for the 2Q of Fiscal 2015)

November 6, 2015

KAKEN PHARMACEUTICAL CO., LTD.

Corporate Communications

Tel: +81-(0)3-5977-5002

Fax: +81-(0)3-5977-5131

Email: koho@kaken.co.jp

ACRUX DDS PTY LTD. et al.

EXHIBIT 1647

IPR Petition for

U.S. Patent No. 7,214,506

1. Summary of Consolidated Financial Statements for the Second Quarter of Fiscal 2015

(Figures less than one million yen have been omitted)

	FY2014 2nd Q	FY2014	FY2015 2nd Q	Y o Y increase (decrease)		FY2015 Forecasts	Y o Y increase (decrease)	
				Yen	%		Yen	%
Net sales	44,232	93,889	54,973	10,740	124.3%	107,900	14,011	114.9%
Operating income	8,806	20,631	18,443	9,636	209.4%	32,200	11,569	156.1%
Ratio of net sales	19.9%	22.0%	33.6%			29.8%		
Ordinary income	8,677	20,394	18,573	9,896	214.1%	32,400	12,006	158.9%
Ratio of net sales	19.6%	21.7%	33.8%			30.0%		
Net income	5,639	12,122	12,483	6,844	221.4%	19,200	7,078	158.4%
Ratio of net sales	12.7%	12.9%	22.7%			17.8%		
Per share profit (Yen)	134.56	290.90	301.39			463.66		

Note: Kaken has conducted a consolidation of common share at rate of one share for every two shares with effective date of October 1, 2015.

Per shar profit has been calculated as if this consolidation of shares was conducted at the bigining of previous fiscal year.

Comprehensive income	6,603	16,607	11,308	4,704	171.2%			
Capital investment	1,156	2,806	1,529	372	132.2%	3,200	394	114.0%
R&D expenses	3,374	7,615	2,965	(408)	87.9%	8,300	685	109.0%
Depreciation and amortization	1,175	2,400	1,039	(135)	88.4%	2,200	(200)	91.7%
Employee number	1,541	1,503	1,482	(59)				

2. Breakdown of Consolidated Net Sales by Segment

(Figures less than one million yen have been omitted)

	FY2014 2nd Q	FY2014	FY2015 2nd Q	Y o Y increase (decrease)	
				Yen	%
Pharmaceuticals, medical devices & agrochemicals	43,005	91,458	53,794	10,788	125.1%
Real estate	1,226	2,431	1,178	(47)	96.1%
Total	44,232	93,889	54,973	10,740	124.3%

KAKEN PHARMACEUTICAL CO., LTD.

3. Summary of Consolidated Balance Sheets

(Figures less than one million yen have been omitted)

	As of September 30, 2014	Ratio	As of March 31, 2015	Ratio	As of September 30, 2015	Ratio	Y o Y increase (decrease)
Assets	106,193	100.0%	115,135	100.0%	124,299	100.0%	9,164
Current assets	58,027	54.6%	69,016	59.9%	79,022	63.6%	10,005
Noncurrent assets	48,166	45.4%	46,118	40.1%	45,277	36.4%	(841)
Liabilities	36,781	34.6%	38,035	33.0%	38,714	31.1%	679
Current liabilities	27,598	26.0%	30,369	26.4%	31,727	25.5%	1,358
Noncurrent liabilities	9,182	8.6%	7,665	6.7%	6,986	5.6%	(679)
Net assets	69,411	65.4%	77,100	67.0%	85,585	68.9%	8,485
Capital stock	23,853	22.5%	23,853	20.7%	23,853	19.2%	-
Capital surplus	11,407	10.7%	11,406	9.9%	11,407	9.2%	0
Retained earnings	48,686	45.8%	52,932	46.0%	62,765	50.5%	9,832
Treasury stock	(16,021)	(15.1%)	(16,098)	(14.0%)	(16,271)	(13.1%)	(172)
Valuation difference on available-for-sale securities	3,040	2.9%	5,478	4.8%	4,188	3.4%	(1,289)
Remeasurements of defined benefit plans	(1,554)	(1.5%)	(472)	(0.4%)	(357)	(0.3%)	114

4. Summary of Consolidated Statements of Cash Flows

(Figures less than one million yen have been omitted)

	FY2014 2Q	FY2014	FY2015 2nd Q	Y o Y increase (decrease)
Net cash provided by (used in) operating activities	3,175	14,737	10,551	7,375
Net cash provided by (used in) investing activities	(795)	473	(1,754)	(959)
Net cash provided by (used in) financing activities	(5,586)	(7,900)	(2,821)	2,764
Cash and cash equivalents at end of period	14,251	24,767	30,742	16,491

5. Summary of Non-consolidated Financial Statements for the Second Quarter of Fiscal 2015

(Figures less than one million yen have been omitted)

	FY2014 2Q	FY2014	FY2015 2Q	Y o Y increase(decrease)		FY2015 Forecasts	Y o Y increase(decrease)	
				Yen	%		Yen	%
Net sales	43,349	91,951	53,851	10,502	124.2%	105,700	13,749	115.0%
Operating income	8,496	19,994	18,119	9,623	213.3%	31,500	11,506	157.5%
Ratio of net sales	19.6%	21.7%	33.6%			29.8%		
Ordinary income	8,411	19,845	18,277	9,866	217.3%	31,800	11,955	160.2%
Ratio of net sales	19.4%	21.6%	33.9%			30.1%		
Net income	5,481	11,777	12,295	6,813	224.3%	16,900	5,123	143.5%
Ratio of net sales	12.6%	12.8%	22.8%			16.0%		
Capital investment	1,137	2,777	1,508	370	132.5%	3,100	323	111.6%
R&D expenses	3,374	7,615	2,965	(408)	87.9%	8,300	685	109.0%
Depreciation and amortization	1,135	2,319	998	(136)	87.9%	2,200	(119)	94.9%
Export volume	2,950	7,220	5,088	2,138	172.5%			
Pharmaceuticals	1,998	4,813	4,231	2,233	211.7%			
Agrochemicals	952	2,407	856	(95)	90.0%			
Employee number	1,523	1,493	1,475	(48)				

6. Breakdown of Non-consolidated Net Sales by Segment

(Figures less than one million yen have been omitted)

	FY2014 2Q	FY2014	FY2015 2Q	Y o Y increase(decrease)		FY2015 Forecasts	Y o Y increase(decrease)	
				Yen	%		Yen	%
Pharmaceuticals & medical devices	40,478	84,444	50,790	10,311	125.5%	98,180	13,736	116.3%
Agrochemicals	1,843	5,472	2,080	236	112.8%	5,580	108	102.0%
Renting real estate	1,027	2,034	981	(46)	95.5%	1,940	(94)	95.4%
Total	43,349	91,951	53,851	10,502	124.2%	105,700	13,749	115.0%

7. Breakdown of Sales by Main Pharmaceuticals and Medical Devices

(Figures less than one million yen have been omitted)

	FY2014 2Q	FY2014	FY2015 2Q	%	FY2015 Forecasts	%
Anti-osteoarthritis Artz	15,600	30,259	15,659	100.4%	30,600	101.1%
Anti-nail fungus Clenafin	1,430	6,857	9,804	685.3%	17,500	255.2%
Post-operative anti-adhesive Septrafilm	5,309	10,791	5,641	106.3%	11,200	103.8%
Anti-hyperlipidemia Lipidil	2,143	4,373	2,237	104.4%	4,600	105.2%
Wound healing agent Fiblast Spray	1,730	3,511	1,816	105.0%	3,600	102.5%
Generic products	6,054	12,380	6,584	108.8%	13,300	107.4%
Sales of Jublia*	1,387	3,318	3,474	250.4%	6,000	180.8%

(* including sales of API and finished product, royalty revenue and milestone revenue)

8. Development Status

Code	Indication	Stage	Remarks
KCB-1D	Periodontitis	Filed	bFGF
KAG-308	Ulcerative colitis	PII	Developed jointly with Asahi Glass Co., Ltd.; Oral-use prostaglandin analog
BBI-4000	Primary focal hyperhidrosis	Preparing for PI	Licensed from Brickell Biotech, Inc.; Topical anticholinergic
SI-657	Enthesopathy	PIII	Developed jointly with Seikagaku Corporation; Additional indication for ARTZ

KAKEN PHARMACEUTICAL CO., LTD.